Shares of Baxter International Inc. BAX slid 4.02% to $34.41 Wednesday, on what proved to be an all-around mixed trading ...

Baxter’s stock price fell to $36.42. Shareholders have lost 7.3% of their capital, which is disappointing considering the S&P ...

Barclays raised the firm’s price target on Baxter (BAX) to $41 from $39 and keeps an Overweight rating on the shares. The firm updated its ...

Barclays analyst Matt Miksic maintained a Buy rating on Baxter International (BAX – Research Report) on March 7 and set a price target of ...

According to a comprehensive report from The Insight Partners, "Parenteral Nutrition Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report" ...

Artificial Intelligence revolutionizes diagnostics, improving disease detection and treatment planning while navigating ethical and data integration challenges.

Jars of pickled gherkins have been recalled due to fears they could pose a risk to those with allergies. Baxter’s Food Group ...

Slamdance is nearing the final day of its 2025 edition, a historic one for the festival founded in 1995 as a scrappy alternative to Sundance. The cinematic showcase has made a new home for itself ...

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025. Joel Grade, Baxter’s chief ...

Baxter reported Q4 adjusted EPS of $0.58 ... recent new product launches and ongoing strength in Drug Compounding. Healthcare Systems & Technologies sales declined 1% to $784 million.